NeRRe Therapeutics CEO, Dr Mary Kerr, interviewed at the 2017 Biotech Showcase by Mike Ward, Chief Content Officer at Datamonitor Healthcare & Scrip Intelligence2017-05-032018-09-14https://www.nerretherapeutics.com/wp-content/uploads/2018/09/logo.pngNeRRe Therapeuticshttps://www.nerretherapeutics.com/wp-content/uploads/2018/09/logo.png200px200px
NeRRe Therapeutics CEO, Dr Mary Kerr, interviewed at the 2017 Biotech Showcase by Mike Ward, Chief Content Officer at Datamonitor Healthcare & Scrip Intelligence
NeRRe Therapeutics is a UK based clinical-stage company developing a unique portfolio of neurokinin (NK) receptor antagonists for the treatment of common debilitating conditions caused by neuronal hypersensitivity.